Pfizer's oral Xeljanz meets endpoints in Phase III ulcerative colitis trials

19 March 2016

US pharma giant Pfizer (NYSE: PFE) on Friday released positive clinical trial results for its rheumatoid arthritis drug Xeljanz (tofacitinib) in the treatment of ulcerative colitis, which could result in an expanded indication for the already marketed drug.

The ulcerative colitis market is expect to grow to a value of $4.2 billion in the top seven markets (USA, France Germany, Italy, Spain, the UK and Japan), accorded to research from Decision Resources. For full-year 2015, Xeljanz generated sales of $523 million. The firm’s shares edged up 1.03% to $29.54 by closed of trading.

Results from OCTAVE Induction 1 and OCTAVE Induction 2, evaluating the efficacy and safety of oral tofacitinib 10mg twice daily (BID) in inducing remission in adult patients with moderately to severely active ulcerative colitis (UC) were presented the 11th Congress of European Crohn's and Colitis Organization (ECCO).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK